Business Description
Neurogene Inc
NAICS : 541714
SIC : 2833
Description
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today's complex devastating neurological diseases into treatable conditions.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 9.56 | |||||
| Equity-to-Asset | 0.84 | |||||
| Debt-to-Equity | 0.11 | |||||
| Debt-to-EBITDA | -0.29 | |||||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 5.44 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Future 3-5Y EPS without NRI Growth Rate | 54.58 |
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.09 | |||||
| Quick Ratio | 9.09 | |||||
| Cash Ratio | 8.8 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -3.28 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -8197.41 | |||||
| Net Margin % | -5756.43 | |||||
| FCF Margin % | -7569.62 | |||||
| ROE % | -57.13 | |||||
| ROA % | -31.85 | |||||
| ROIC % | -263.69 | |||||
| ROC (Joel Greenblatt) % | -261.77 | |||||
| ROCE % | -34.89 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 416.18 | |||||
| PB Ratio | 2.17 | |||||
| Price-to-Tangible-Book | 2.17 | |||||
| EV-to-EBIT | -4.04 | |||||
| EV-to-EBITDA | -4.31 | |||||
| EV-to-Revenue | 232.56 | |||||
| EV-to-FCF | -3.03 | |||||
| Price-to-Net-Current-Asset-Value | 2.55 | |||||
| Price-to-Net-Cash | 2.65 | |||||
| Earnings Yield (Greenblatt) % | -24.75 | |||||
| FCF Yield % | -20.85 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Neurogene Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.859 | ||
| EPS (TTM) (€) | -2.835 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0.038503 | ||
| 20-Day SMA (€) | 14.5 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 14.5 - 16.4 | ||
| Shares Outstanding (Mil) | 14.85 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Neurogene Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Neurogene Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Neurogene Inc Frequently Asked Questions
What is Neurogene Inc(FRA:UU8)'s stock price today?
The current price of FRA:UU8 is €14.50. The 52 week high of FRA:UU8 is €16.40 and 52 week low is €14.50.
When is next earnings date of Neurogene Inc(FRA:UU8)?
The next earnings date of Neurogene Inc(FRA:UU8) is 2025-03-18 Est..
Does Neurogene Inc(FRA:UU8) pay dividends? If so, how much?
Neurogene Inc(FRA:UU8) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers